5-[5-[2-Chloroethyl(2-hydroxyethyl)amino]-1-methylbenzimidazol-2-yl]pentan-2-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 5-[5-[2-Chloroethyl(2-hydroxyethyl)amino]-1-methylbenzimidazol-2-yl]pentan-2-one
• 英文别名: 5-[5-[2-chloroethyl(2-hydroxyethyl)amino]-1-methylbenzimidazol-2-yl]pentan-2-one
• 化学式: C₁₇H₂₄ClN₃O₂
• 分子量: 337.8
• InChiKey: FIARYUREKPKOOM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  23
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  58.4
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Bendamustine Solid Dispersions And Continuous Infusion
  申请人：Voudouris Vasilios

  公开号：US20150258069A1

  公开（公告）日：2015-09-17

  Provided herein are pharmaceutical compositions comprising nitrogen mustard, for example bendamustine hydrochloride, solid dispersions substantially free of degradants. Also provided are methods of producing and administering nitrogen mustards and in particular bendamustine hydrochloride solid dispersions substantially free of degradants. The pharmaceutical compositions can be used for any disease that is sensitive to treatment with bendamustine hydrochloride, such as neoplastic diseases.

  本文提供了含有氮芥的制药组合物，例如盐酸苯达莫司汀，这些组合物是基本无降解物的固体分散体。同时提供了生产和给药氮芥（特别是基本无降解物的盐酸苯达莫司汀固体分散体）的方法。这些制药组合物可用于对盐酸苯达莫司汀敏感的任何疾病，例如肿瘤性疾病。
• BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS
  申请人：Cephalon, Inc.

  公开号：US20140148490A1

  公开（公告）日：2014-05-29

  The present invention provides pharmaceutical formulations of lyophilized bendamustine suitable for pharmaceutical use. The present invention further provides methods of producing lyophilized bendamustine. The pharmaceutical formulations can be used for any disease that is sensitive to treatment with bendamustine, such as neoplastic diseases.
• Bendamustine Pharmaceutical Compositions
  申请人：Voudouris Vasilios

  公开号：US20150065549A1

  公开（公告）日：2015-03-05

  Provided herein are pharmaceutical formulations of dry-powder bendamustine suitable for pharmaceutical use. Also provided are methods of producing dry-powder bendamustine. The pharmaceutical formulations can be used for any disease that is sensitive to treatment with bendamustine, such as neoplastic diseases.
• BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS
  申请人：CEPHALON, INC.

  公开号：US20150374671A1

  公开（公告）日：2015-12-31

  The present invention provides pharmaceutical formulations of lyophilized bendamustine suitable for pharmaceutical use. The present invention further provides methods of producing lyophilized bendamustine. The pharmaceutical formulations can be used for any disease that is sensitive to treatment with bendamustine, such as neoplastic diseases.
• US8791270B2
  申请人：——

  公开号：US8791270B2

  公开（公告）日：2014-07-29